NightHawk Biosciences Inc (NHWK)

[dia76ca]

In NMIBC HS-410 reduced TIL negative tumours from ~60% to ~15%. In other words it turned 75% of "cold" tumours into "hot" tumours. If it does the same in the lung cancer trial with the combination of H110 and Opdivo it will be an outstanding result. In both bladder and lung cancer it will mean patients for a phase 3 trial can be selected on the basis of their TIL status with the expectation that some 75% of patients will be responders. This will lead to a very highly improved rate of PFS and OS. Many BP's will be very interested. According to Wolf BMY, Merck and AZN will be looking at the results! Partnership or buyout? A competition for either one would be good news for HTBX investors.